79 results on '"Piscione, Federico"'
Search Results
2. High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study
- Author
-
De Rosa, Roberta, Palmerini, Tullio, De Servi, Stefano, Belmonte, Marta, Crimi, Gabriele, Cornara, Stefano, Calabrò, Paolo, Cattaneo, Marco, Maffeo, Diego, Toso, Anna, Bartorelli, Antonio, Palmieri, Cataldo, De Carlo, Marco, Capodanno, Davide, Genereux, Philippe, Angiolillo, Dominick, Piscione, Federico, and Galasso, Gennaro
- Published
- 2018
- Full Text
- View/download PDF
3. Inotropic stimulation by dobutamine increases left ventricular regional function at the expense of metabolism in hibernating myocardium
- Author
-
Indolfi, Ciro, Piscione, Federico, Perrone-Filardi, Pasquale, Prastaro, Mariella, Di Lorenzo, Emilio, Sacca, Luigi, Salvatore, Marco, Condorelli, Mario, and Chiariello, Massimo
- Subjects
Dobutamine -- Physiological aspects ,Heart muscle ,Health - Published
- 1996
4. Are ioxaglate and iopamidol equally safe and well tolerated in cardiac angiography? A randomized, double-blind clinical study
- Author
-
Piscione, Federico, Focaccio, Amelia, Santinelli, Vincenzo, De Paola, Mario, Villari, Bruno, Spinazzi, Alberto, Condorelli, Mario, and Chiariello, Massimo
- Subjects
Myelography -- Physiological aspects ,Ioxaglate -- Physiological aspects ,Contrast media -- Evaluation ,Health - Abstract
Contrast agents are compounds used to enhance the contrast of images obtained with angiography, X-ray imaging of blood vessels. Formerly, hyperosmolar agents, which had high levels of dissolved substances, were associated with harmful effects on blood pressure and heart muscle contractility. New, low-osmolar agents have been developed; some are ionized, or charged, and paired with sodium ions, while others are nonionic. Some studies suggest that ionized low-osmolar agents such as ioxaglate produce fewer disturbances in the rhythm of heart beat than nonionic contrast agents such as iopamidol. Ioxaglate contains levels of sodium ions which are similar to physiological levels. The effectiveness and side effects of ioxaglate and iopamidol were evaluated in 50 patients who had symptoms of ischemic heart disease. Hemodynamic (blood vessel and heart pumping parameters) changes, diagnostic effectiveness, and side effects were similar in groups given either agent. However, patients given iopamidol developed significantly more arrhythmias in ventricular beats. The study suggests that both agents are safe and effective contrast agents, but iopamidol is associated with a greater risk of ventricular arrhythmias, possibly due to its lack of sodium ions. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1990
5. Digoxin-induced vasoconstriction of normal and atherosclerotic epicardial coronary arteries
- Author
-
Indolfi, Ciro, Piscione, Federico, Russolillo, Enrico, Villari, Bruno, Golino, Paolo, Ambrosini, Vittorio, Condorelli, Mario, and Chiariello, Massimo
- Subjects
Digoxin -- Health aspects ,Vasoconstriction -- Physiological aspects ,Atherosclerosis -- Drug therapy ,Coronary arteries ,Health - Published
- 1991
6. Complicated acute type B aortic dissection involving the arch: Treatment by simultaneous hybrid approach under local anesthesia
- Author
-
Iannelli, Gabriele, Monaco, Mario, Di Tommaso, Luigi, and Piscione, Federico
- Subjects
Surgery ,Health - Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jtcvs.2007.04.077 Byline: Gabriele Iannelli (a), Mario Monaco (a), Luigi Di Tommaso (b), Federico Piscione Author Affiliation: (a) Department of Cardiac Surgery, University 'Federico II,' Naples, Italy (b) Department of Cardiology, University 'Federico II,' Naples, Italy Article History: Received 20 March 2007; Accepted 19 April 2007
- Published
- 2008
7. Usefulness of late coronary thrombolysis (recombinant tissue-type plasminogen activator) in preserving left ventricular function in acute myocardial infarction
- Author
-
Villari, Bruno, Piscione, Federico, Bonaduce, Domenico, Golino, Paolo, Lanzillo, Tonino, Condorelli, Mario, and Chiarello, Massimo
- Subjects
Tissue plasminogen activator -- Evaluation ,Tissue plasminogen activator -- Physiological aspects ,Heart attack -- Drug therapy ,Tissue plasminogen activator -- Dosage and administration ,Thrombolytic drugs -- Physiological aspects ,Health - Abstract
This study assesses whether administration of recombinant tissue-type plasminogen activator (rt-PA) up to 8 hours after onset of symptoms of acute myocardial infarction (AMI) may result in a significant improvement in left ventricular function. Sixty patients were classified into 3 groups: group A (n = 21) received rt-PA within 4 hours from symptom onset; the remaining 39 patients, admitted between 4 and 8 hours, were randomized into 2 groups--group B (n = 19) received rt-PA, and group C (n = 21) was treated with conventional therapy. Coronary and left ventricular angiograms were recorded 8 to 10 days after rt-PA administration. The patency rate of the infarct-related artery was 76% in group A, and 63 and 35% in group B and C, respectively. The Thrombolysis in Myocardial Infarction trial perfusion grade was higher in group A and B than in group C (A vs C: p [is less than]0.005; B vs C: p [is less than]0.01). Left ventricular ejection fraction was significantly higher in group A (60.2 [+ or -] 10%) and B (54.7 [+ or -] 12%) compared with group C (44.2 [+ or -] 12%) (A vs C: p [is less than]0.01; B vs C: p [is less than]0.05). Regional wall motion of the entire ischemic zone was better in group A and B than in group C (A vs C: p [is less than]0.001; B vs C: p [is less than]0.01). In contrast, the kinesis of the central ischemic zone was significantly better in group A than in both group B and C (A vs B: p [is less than]0.05; A vs C: p [is less than]0.001). The number of hypokinetic, akinetic and dyskinetic segments were lower in group A and B than in group C (A vs B: p [is less than]0.01, B vs C:p [is less than]0.05 and A vs C: p [is less than]0.01 and B vs C: p [is less than]0.01, respectively). Thus, these data confirm the efficacy of early thrombolysis and suggest that late reperfusion may act beneficially in preserving left ventricular volumes and function. (Am J Cardiol 1990;66:1281-1286), In acute myocardial infarction (AMI, or heart attack), the blood supply to the heart is impaired by the blockage of one or more coronary arteries; this results in damage to the heart muscle and may cause death. The treatment of choice for AMI is prompt administration of thrombolytic agents, which break up the clot blocking the coronary artery, restoring blood flow to the heart. There is controversy over how long after the beginning of an AMI thrombolytic treatment can be administered before heart damage becomes irreversible. To determine the effects of late thrombolysis on the outcome of AMI, 60 patients admitted to a coronary care unit with the diagnosis of AMI were assessed. Recombinant tissue-type plasminogen activator (rt-PA; a substance that causes dissolution of fibrin clots) was administered directly into the blocked coronary artery of patients who were diagnosed with AMI early (less than four hours after the onset of symptoms - early treatment group). A second group, in whom the diagnosis of AMI was made between four and eight hours after symptom onset, received rt-PA later in the course of the heart attack (late treatment group). A third group, also with delayed diagnosis of AMI, received only conventional therapy (vasodilators and anticoagulant drugs). On most indices of heart function, the early and late treatment groups tested significantly better than the group who received conventional therapy; patency of the infarct-related artery, contractility of the left ventricle, and motility of the ischemic (blood deprived) area were all comparably improved after either early or late thrombolysis, compared with conventional therapy. One index of cardiac function, the number of segments of the heart with impaired motility, showed less dramatic improvement in the late treatment group than in the early treatment group, but the heart function of both rt-PA groups was significantly better than the conventional therapy group. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1990
8. Effects of intravenous verapamil on left ventricular relaxation and filling in stable angina pectoris
- Author
-
Betocchi, Sandro, Piscione, Federico, Perrone-Filardi, Pasquale, Pace, Leonardo, Cappelli-Bigazzi, Maurizio, Alfano, Bruno, Ciarmiello, Andrea, Salvatore, Marco, Condorelli, Mario, and Chiariello, Massimo
- Subjects
Calcium channel blockers -- Physiological aspects ,Heart failure -- Causes of ,Angina pectoris -- Drug therapy ,Heart ventricle, Left -- Physiological aspects ,Verapamil -- Physiological aspects ,Health - Abstract
Left ventricular (LV) diastolic function is often impaired in coronary artery disease (CAD). To assess whether verapamil could improve LV diastolic properties, 12 patients with CAD undergoing right-and left-sided cardiac catheterization, as well as simultaneous radionuclide angiography, were studied before and during intravenous administration of verapamil (0.1 mg/kg as a bolus followed by 0.007 mg/kg/min). The heart rate was kept constant by atrial pacing in both studies. LV pressure-volume relations were obtained. Verapamil decreased LV systolic pressure (130 [+ or -] 22 to 117 [+ or -] 16 mm Hg, p (Am J Cardiol 1990;66:818-825), Left ventricular (LV) diastolic function refers to the relaxation phase of the heartbeat, specifically when the left atrium contracts and oxygenated blood flows into the relaxed LV chamber. Angina pectoris (chest pain caused by decreased blood flow to the heart) can impair this function by slowing ventricular relaxation and reducing early filling of the LV. This diastolic dysfunction may induce symptoms of congestive heart failure even when ventricular systolic function (the ability to pump oxygenated blood into the systemic circulation) is normal. The authors investigated whether treatment with verapamil, a calcium channel blocker usually used to treat angina, would reverse diastolic dysfunction. Verapamil is known to improve LV relaxation and filling for some conditions, and noninvasive studies had reported similar effects in patients with coronary artery disease (CAD). It was important to determine whether verapamil-related improvements in LV relaxation and filling were the result of improved diastolic function or increased filling pressure. Twelve patients with CAD, who were undergoing diagnostic heart catheterization and angiography (X-ray), were studied before and during intravenous administration of verapamil. When measurements were being taken, the heart rate was kept constant by a cardiac pacemaker. Comparison with a control group was not possible because healthy people could not be subjected to such invasive procedures. The results of the study indicate that administration of verapamil is useful in treating coronary artery disease. Its effects on the myocardium, or heart muscle, improved LV relaxation and, thereby, increased the peak filling rate. Verapamil also led to a higher preload, resulting in enhanced filling, and reduced afterload, resulting in improved relaxation. Therefore, verapamil affects LV function and early filling as a result of both direct action on the heart muscle and changes in load. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1990
9. Response to Letter of Li et al.: How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing?
- Author
-
De Rosa, Roberta, Palmerini, Tullio, and Piscione, Federico
- Published
- 2018
- Full Text
- View/download PDF
10. Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.
- Author
-
Russo, Juan J., Goodman, Shaun G., Cantor, Warren J., Ko, Dennis T., Bagai, Akshay, Tan, Mary K., Di Mario, Carlo, Halvorsen, Sigrun, Le May, Michel, Fernandez-Avilés, Francisco, Scheller, Bruno, Armstrong, Paul W., Borgia, Francesco, Piscione, Federico, Sanchez, Pedro L., and Yan, Andrew T.
- Abstract
Background: The efficacy and safety of pharmacoinvasive strategy following fibrinolysis for ST-elevation myocardial infarction (STEMI) in relation to renal function have not been established.Methods: Using patient-level data from 4 randomized controlled trials, we examined the efficacy and safety of pharmacoinvasive versus standard treatment after fibrinolysis for STEMI. Patients were stratified based on the estimated glomerular filtration rate (eGFR) on presentation (<60 mL/min/1.73 m2 vs ≥60 mL/min/1.73 m2). The primary outcome was the composite of death or reinfarction at 30 days.Results: Of 2,029 patients, 457 (23%) had an eGFR<60 mL/min/1.73 m2. Patients with eGFR<60 mL/min/1.73 m2 were older and had higher Thrombolysis in Myocardial Infarction risk scores. Compared with patients with eGFR≥60 mL/min/1.73 m2, patients with renal dysfunction had higher rates of the primary outcome (5.3% vs 11.8%, respectively; P<.001). There was no significant heterogeneity in the treatment effect of pharmacoinvasive strategy on the primary outcome (P heterogeneity=.73) or the rate of death or reinfarction at 1 year (P heterogeneity=.64) in relation to eGFR. Patients with renal dysfunction had higher rates of in-hospital major bleeding compared with patients with eGFR ≥60 mL/min/1.73 m2 (7.7% vs 4.3%, respectively; P=.004); however, there was no difference in bleeding events between treatment arms in the overall cohort or in relation to eGFR (P heterogeneity=.67).Conclusions: Renal impairment is associated with increased rates of adverse events in STEMI patients treated with fibrinolysis. However, the safety and efficacy of pharmacoinvasive strategy are preserved in patients with renal impairment on presentation. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
11. Assessment of left ventricular function using radionuclide angiography after dipyridamole infusion
- Author
-
Indolfi, Ciro, Betocchi, Sandro, Piscione, Federico, Perrone-Filardi, Pasquale, Salvatore, Marco, and Chiariello, Massimo
- Subjects
Coronary heart disease -- Diagnosis ,Radionuclide angiography -- Methods -- Physiological aspects ,Dipyridamole -- Physiological aspects -- Methods ,Heart ventricle, Left -- Physiological aspects -- Methods ,Health ,Diagnosis ,Physiological aspects ,Methods - Abstract
Thirty-six patients with significant coronary artery stenosis and no previous myocardial infarction and 25 subjects with normal coronary arteries underwent [99m.sup.Tc] RNV before and after coronary vasodilatation induced by dipyridamole, [...]
- Published
- 1989
12. Effects of aortic counterpulsation in 6 cases of fulminant myocarditis.
- Author
-
Vincenza Polito, Maria, Ravera, Amelia, Menneila, Raffaele, Ferrara, Saverio, Baldi, Cesare, Citro, Rodolfo, Di Maio, Marco, Vigorito, Francesco, Farina, Rosario, and Piscione, Federico
- Published
- 2015
- Full Text
- View/download PDF
13. Relationship Between Time to Invasive Assessment and Clinical Outcomes of Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Segment Elevation Myocardial Infarction: A Patient-Level Analysis of the Randomized Early Routine...
- Author
-
Madan, Mina, Halvorsen, Sigrun, Di Mario, Carlo, Tan, Mary, Westerhout, Cynthia M., Cantor, Warren J., Le May, Michel R., Borgia, Francesco, Piscione, Federico, Scheller, Bruno, Armstrong, Paul W., Fernandez-Aviles, Francisco, Sanchez, Pedro L., Graham, John J., Yan, Andrew T., and Goodman, Shaun G.
- Abstract
Objectives This study investigated the relationship between time to invasive assessment and outcomes among ST-segment elevation myocardial infarction patients randomized to early angiography after fibrinolysis. Background The optimal timing of coronary angiography after fibrinolysis and the association with clinical outcomes is uncertain. Methods Patient-level data from 6 randomized trials, with a median time to angiography <12 h after fibrinolysis, were pooled. The primary endpoint was 30-day death or reinfarction. The key secondary endpoint was in-hospital major bleeding. The relationship between fibrinolysis to angiography time and symptom onset to angiography time with outcomes was studied using 2- and 4-h intervals, respectively, and in multivariable models. Results Among 1,238 patients, the median fibrinolysis to angiography time was 165 min, and the median symptom onset to angiography time was 5.33 h. The primary and key secondary endpoints occurred in 5.7% and 4.7%, respectively. These main endpoints did not vary significantly with increasing fibrinolysis to angiography time. Early angiography (<2 h) after fibrinolysis was not associated with increased bleeding. Recurrent ischemia increased with increasing fibrinolysis to angiography time (3.7% to 7.9%, p for trend = 0.02). Thirty-day and 1-year death/reinfarction and 30-day recurrent ischemia increased significantly with increasing symptom onset to angiography time. Neither fibrinolysis to angiography time nor symptom onset to angiography time was an independent predictor of the primary endpoint. Only symptom onset to angiography time was an independent predictor of 1-year death/reinfarction (hazard ratio: 1.07, 95% confidence interval: 1.02 to 1.12, p = 0.01). Conclusions Very early angiography (<2 h) after fibrinolysis was not associated with an increased risk of 30-day death/reinfarction or in-hospital major bleeding, and angiography within 4 h after fibrinolysis was associated with reduced 30-day recurrent ischemia. A shorter symptom onset to angiography time (<4 h) was associated with reduced 30-day and 1-year death/reinfarction and 30-day recurrent ischemia. In the current environment of regional networks of 24/7 primary percutaneous coronary intervention (PCI) centers, the clinical implication of these findings is that patients initially treated with fibrinolysis should also be promptly transferred to the nearest PCI center for immediate angiography and PCI. (Early Percutaneous Coronary Intervention [PCI] After Fibrinolysis Versus Standard Therapy in ST Segment Elevation Myocardial Infarction [STEMI] Patients; NCT01014182 ) [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The GEPRESS Study.
- Author
-
Palmerini, Tullio, Calabrò, Paolo, Piscione, Federico, De Servi, Stefano, Cattaneo, Marco, Maffeo, Diego, Toso, Anna, Bartorelli, Antonio, Palmieri, Cataldo, De Carlo, Marco, Capodanno, Davide, Barozzi, Chiara, Tomasi, Luciana, Della Riva, Diego, Mariani, Andrea, Taglieri, Nevio, Reggiani, Letizia Bacchi, Bianchi, Renatomaria, De Rosa, Roberta, and Mariani, Matteo
- Abstract
Objectives The aim of this study was to investigate the association between high on-treatment platelet reactivity (HPR) and the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score (SS) for risk prediction of major adverse cardiovascular events (MACE) in patients with non–ST-segment elevation acute coronary syndrome (NSTEACS) undergoing percutaneous coronary intervention (PCI). Background Platelet function testing may be used to optimize antiplatelet therapy in high-risk patients, but identification of this category of patients remains challenging. Methods The GEPRESS (Gene Polymorphism, Platelet Reactivity, and the Syntax Score) study was a prospective, multicenter, observational study enrolling 1,053 patients with NSTEACS undergoing PCI and treated with clopidogrel. The platelet reactivity index (PRI) was measured at 3 time points: before PCI, at hospital discharge, and 1 month after PCI. Genetic variants of clopidogrel metabolism were determined in 750 patients. Patients were stratified by the presence of HPR (PRI >50%) and by tertile of the SS (upper SS tertile ≥15). The primary objective of this study was the risk of MACE in the period between 1 month and 1 year. Results Between 1 month and 1 year, 1-month HPR was an independent predictor of MACE in patients with an SS ≥15, but not in those with an SS <15, displaying a 5-fold increase in event rates (10.4% vs. 2.5%; p < 0.0001). CYP2C19*2 was the only single nucleotide polymorphism associated with HPR, but it was not associated with MACE. Although there was a significant variability in the PRI across the 1-month period, predischarge HPR and SS effectively stratified the risk of subsequent MACE up to 1-year follow-up. Conclusions In clopidogrel-treated patients with NSTEACS undergoing PCI, HPR was independently associated with an increased risk of MACE only in the presence of a high SS. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
15. Echocardiographic Correlates of Acute Heart Failure, Cardiogenic Shock, and In-Hospital Mortality in Tako-Tsubo Cardiomyopathy.
- Author
-
Citro, Rodolfo, Rigo, Fausto, D'Andrea, Antonello, Ciampi, Quirino, Parodi, Guido, Provenza, Gennaro, Piccolo, Raffaele, Mirra, Marco, Zito, Concetta, Giudice, Roberta, Patella, Marco Mariano, Antonini-Canterin, Francesco, Bossone, Eduardo, Piscione, Federico, and Salerno-Uriarte, Jorge
- Abstract
Objectives: The purpose of this study was to determine clinical and echocardiographic correlates of acute heart failure, cardiogenic shock and in-hospital mortality in a large cohort of tako-tsubo cardiomyopathy (TTC) patients. Background: Despite good long-term prognosis, life-threatening complications due to hemodynamic instability can occur early in TTC patients. Methods: The study population consisted of 227 patients (66.2 ± 12.2 years of age; females, 90.3%) enrolled in the Tako-tsubo Italian Network, undergoing transthoracic two-dimensional echocardiography on admission and at short-term follow-up (4.3 [4 to 6] weeks). Patients were divided into two groups according to the presence or absence of major adverse events, a composite of acute heart failure, cardiogenic shock, and in-hospital mortality. Results: Major adverse events occurred in 59 patients (25.9%). The variables for elderly patients ≥75 years of age (42.4% vs. 23.8%; p = 0.011): left ventricular (LV) ejection fraction (35.1 ± 5.9% vs. 38.4 ± 4.6%, p < 0.001), wall motion score index (1.9 ± 0.2 vs. 1.7 ± 0.2, p < 0.001), E/e′ ratio (13.5 ± 4.3 vs. 9.9 ± 3.3 [where E/e′ is ratio of mitral E peak velocity and averaged e′ velocity], p < 0.001), LV outflow tract obstruction (23.7 vs. 8.9%, p = 0.006), pulmonary artery systolic pressure (47.4 ± 12.3 mm Hg vs. 38.0 ± 9.2 mm Hg; p < 0.001), right ventricular involvement (28.8 vs. 9.5%; p < 0.001), and reversible moderate-to-severe mitral regurgitation (49.1 vs. 11.9%; p < 0.001), were significantly different between groups and were associated with adverse events. At multivariate analysis, LV ejection fraction (HR: 0.92; 95% CI: 0.89 to 0.95; p < 0.001), E/e′ ratio (HR: 1.13; 95% CI: 1.02 to 1.24; p = 0.011), reversible moderate to severe mitral regurgitation (HR: 3.25; 95% CI: 1.16 to 9.10; p = 0.025), and age ≥75 years (HR: 2.81; 95% CI: 1.05 to 7.52; p = 0.039) were independent correlates of major adverse events. Conclusions: Echocardiographic parameters provide additional information compared to other variables routinely used in clinical practice to identify patients at higher risk of hemodynamic deterioration and poor in-hospital outcome, allowing prompt institution of appropriate pharmacological treatment and adequate mechanical support. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
16. Early Aggressive Versus Initially Conservative Treatment in Elderly Patients With Non–ST-Segment Elevation Acute Coronary Syndrome: A Randomized Controlled Trial.
- Author
-
Savonitto, Stefano, Cavallini, Claudio, Petronio, A. Sonia, Murena, Ernesto, Antonicelli, Roberto, Sacco, Alice, Steffenino, Giuseppe, Bonechi, Francesco, Mossuti, Ernesto, Manari, Antonio, Tolaro, Salvatore, Toso, Anna, Daniotti, Alessandro, Piscione, Federico, Morici, Nuccia, Cesana, Bruno M., Jori, M. Cristina, and De Servi, Stefano
- Subjects
TREATMENT of acute coronary syndrome ,OLDER patients ,RANDOMIZED controlled trials ,ELECTROCARDIOGRAPHY ,CORONARY arterial radiography ,TREATMENT effectiveness - Abstract
Objectives: This study sought to determine the risk versus benefit ratio of an early aggressive (EA) approach in elderly patients with non–ST-segment elevation acute coronary syndromes (NSTEACS). Background: Elderly patients have been scarcely represented in trials comparing treatment strategies in NSTEACS. Methods: A total of 313 patients ≥75 years of age (mean 82 years) with NSTEACS within 48 h from qualifying symptoms were randomly allocated to an EA strategy (coronary angiography and, when indicated, revascularization within 72 h) or an initially conservative (IC) strategy (angiography and revascularization only for recurrent ischemia). The primary endpoint was the composite of death, myocardial infarction, disabling stroke, and repeat hospital stay for cardiovascular causes or severe bleeding within 1 year. Results: During admission, 88% of the patients in the EA group underwent angiography (55% revascularization), compared with 29% (23% revascularization) in the IC group. The primary outcome occurred in 43 patients (27.9%) in the EA group and 55 (34.6%) in the IC group (hazard ratio [HR]: 0.80; 95% confidence interval [CI]: 0.53 to 1.19; p = 0.26). The rates of mortality (HR: 0.87; 95% CI: 0.49 to 1.56), myocardial infarction (HR: 0.67; 95% CI: 0.33 to 1.36), and repeat hospital stay (HR: 0.81; 95% CI: 0.45 to 1.46) did not differ between groups. The primary endpoint was significantly reduced in patients with elevated troponin on admission (HR: 0.43; 95% CI: 0.23 to 0.80), but not in those with normal troponin (HR: 1.67; 95% CI: 0.75 to 3.70; p for interaction = 0.03). Conclusions: The present study does not allow a definite conclusion about the benefit of an EA approach when applied systematically among elderly patients with NSTEACS. The finding of a significant interaction for the treatment effect according to troponin status at baseline should be confirmed in a larger size trial. (Italian Elderly ACS Study; NCT00510185) [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
17. A new approach to percutaneous coronary revascularization in patients requiring undeferrable non-cardiac surgery
- Author
-
Piscione, Federico, Cassese, Salvatore, Galasso, Gennaro, Cirillo, Plinio, Esposito, Giovanni, Rapacciuolo, Antonio, Leosco, Dario, Piccolo, Raffaele, De Rosa, Roberta, and Chiariello, Massimo
- Subjects
- *
REVASCULARIZATION (Surgery) , *PLATELET aggregation inhibitors , *ENDOVASCULAR surgery , *SURGICAL stents , *ANGIOPLASTY , *TREATMENT effectiveness - Abstract
Abstract: Background: Optimal strategy for patients who need coronary revascularization before undeferrable non-cardiac surgery is still unknown. We performed a pilot study of dual antiplatelet therapy discontinuation followed by major non-cardiac surgery and endovascular aortic repair early after successful endothelial-progenitor cell-capture coronary stent deployment. Methods and results: Thirty consecutive patients underwent coronary angioplasty plus stenting, before upcoming endovascular or surgical procedures requiring early interruption of antiplatelet therapy. An optimal acute procedural result was observed in all patients. Antiplatelet therapy was stopped before surgery in all patients, achieving an average antiplatelet therapy time of 12.2±3.9days. Surgery was performed after antiplatelet therapy interruption at an average time interval from revascularization of 17.2±3.9days. No patient suffered cardiac events during the perioperative period. At thirty day follow-up after surgery there were no cardiac events in all patients. Conclusions: Our preliminary data might suggest a role for EPC-capture stent in patients requiring surgical procedures early after coronary stent placement. Further studies on larger population are needed to confirm the clinical impact of our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
18. Concomitant coronary and peripheral arterial disease: Relationship between the inflammatory status of the affected limb and the severity of coronary artery disease.
- Author
-
Brevetti, Gregorio, Piscione, Federico, Schiano, Vittorio, Galasso, Gennaro, Scopacasa, Francesco, and Chiariello, Massimo
- Subjects
PERIPHERAL vascular diseases ,CORONARY disease ,INFLAMMATION ,LEG blood-vessels ,ATHEROSCLEROSIS ,BLOOD circulation - Abstract
Objective: In coronary artery disease (CAD), concomitant peripheral arterial disease (PAD) entails increased systemic inflammatory profile and more severe coronary atherosclerosis. We investigated the relationship between the inflammatory status in the affected limb and CAD severity. Methods: In 46 CAD+PAD and 31 CAD-alone patients, the inflammatory status of the leg circulation was measured by the transfemoral gradients of neutrophil myeloperoxidase (MPOx) content and interleukin-6 (IL-6). CAD severity was defined by evaluating coronary artery endothelial function, number of significant coronary stenoses, and prevalence of three-vessel CAD and myocardial infarction (MI). Results: In the affected limb of CAD+PAD patients, the transfemoral gradients of neutrophil MPOx content and IL-6 were higher (P < .01, for both) than in the healthy leg of CAD-only patients. At multivariate analysis, CAD+PAD patients with transfemoral gradients of MPOx and IL-6 > median had a more compromised coronary artery endothelial function (P < .05, for both). Furthermore, CAD+PAD patients with transfemoral gradients of neutrophil MPOx content > median showed an independent association with a greater number of significant coronary stenoses, and a greater prevalence of three-vessel CAD and previous MI (P < .01, for all). A more severe coronary atherosclerosis was observed also in CAD+PAD patients with transfemoral gradients of IL-6 > median vs those with IL-6 < median, although differences were not statistically significant. Conclusion: In CAD patients, the coexistence of PAD does not necessarily entail a more severe coronary atherosclerosis. Only those with an inflammatory status of the affected limb presents more severe CAD. Future studies will clarify whether the presence of peripheral inflammation plays a mechanistic role in CAD evolution. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
19. In concomitant coronary and peripheral arterial disease, inflammation of the affected limbs predicts coronary artery endothelial dysfunction
- Author
-
Brevetti, Gregorio, Piscione, Federico, Cirillo, Plinio, Galasso, Gennaro, Schiano, Vittorio, Barbato, Emanuele, Scopacasa, Francesco, and Chiariello, Massimo
- Subjects
- *
CORONARY disease , *PERIPHERAL vascular diseases , *ATHEROSCLEROSIS , *INTERLEUKIN-6 , *C-reactive protein , *CARDIOVASCULAR diseases risk factors , *INFLAMMATION - Abstract
Abstract: Background: In coronary artery disease (CAD), concomitant peripheral arterial disease (PAD) entails more severe coronary atherosclerosis. We investigated whether the inflammatory status of affected limbs impairs coronary artery endothelial function (CAEF). Methods: We measured the neutrophil myeloperoxidase content (NMPOxC) and plasma levels of interleukin-6 and C-reactive protein in the aorta, femoral vein, and coronary sinus of 22 CAD+PAD and 18 CAD-alone patients. CAEF was assessed by the cold pressure test. Human coronary artery endothelial cells (HCAECs) were incubated with serum from the femoral vein and aorta of CAD+PAD patients to determine whether blood leaving the affected limb activates HCAECs. Results: In CAD+PAD patients, NMPOxC was higher across the femoral circulation than across the coronary circulation (p <0.01); it was also higher than across healthy femoral circulation of CAD patients (p <0.01). These findings apply also to interleukin-6, but not to C-reactive protein. The transfemoral gradient of NMPOxC and interleukin-6 significantly correlated with CAEF. The NMPOxC/CAEF relationship was much greater after exercise (R =0.79, p <0.001), which increased neutrophil activation across the affected circulation. The post-exercise association remained significant after adjustment for potential confounders (p <0.01). Serum from the affected limb of CAD+PAD patients induced, in vitro, a significant release of MCP-1 from HCAECs versus serum from the aorta of the same patients (630 [550–740] vs. 547 [490–620]; p <0.05). Conclusions: In CAD+PAD, triggers from the affected circulation may activate the endothelium at distant sites. Thus, PAD, besides being a marker of cardiovascular risk, could exert a mechanistic function in CAD progression. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
20. Abciximab in elderly with Acute Coronary Syndrome invasively treated: Effect on outcome
- Author
-
Galasso, Gennaro, Piscione, Federico, Furbatto, Fulvio, Leosco, Dario, Pierri, Adele, Rosa, Roberta De, Cirillo, Plinio, Rapacciuolo, Antonio, Esposito, Giovanni, and Chiariello, Massimo
- Subjects
- *
CHEMICAL inhibitors , *MYOCARDIAL infarction , *DISEASES in older people , *HEALTH outcome assessment , *TRANSLUMINAL angioplasty , *BLOOD platelet aggregation , *REGRESSION analysis , *PATIENTS , *THERAPEUTICS - Abstract
Abstract: Older age is an independent predictor of mortality after percutaneous coronary intervention (PCI) in patients with Non-ST elevation Acute Coronary Syndrome (ACS). GPIIb/IIIa inhibitors are proved to improve outcome in high risk patients, but conflicting data are available about the effects of these inhibitors in elderly. Accordingly, we studied a consecutive population of elderly patients undergoing PCI for Non-ST elevation ACS. A total of 500 patients were divided in: GPI group (247 pts; mean age 77±1.9 years) treated by stenting plus abciximab and, no GPI group (253 pts; mean age 77±2.4 years) treated by stenting alone. Propensity analysis was used to account for the nonrandomized use of GPIIb/IIIa inhibitors. During hospitalization, incidence of death was similar among groups (3.2% vs 4.6%) without difference regarding incidence of major (1.6% vs 1.1%) and minor bleedings (4% vs 3%). At long-term follow-up the rate of death was significantly lower in GPI group (4.5% vs 12.3%; p =0.002) as well as the rate of acute myocardial infarction (2.8% vs 11.1%; p =0.0001), and pre-PCI (5.7% vs 13.4%; p =0.003). Cox regression analysis identified abciximab use as an independent predictor of lower long-term major adverse cardiac event (MACE) after adjustment for propensity score (Exp (B) 0.620, 95%CI 0.394–0.976, p =0.039). Our results suggest that addition of abciximab to stenting improves outcome in elderly patients with Non-ST elevation ACS, leading to an absolute benefit for reduction of death and MACE, with an acceptable rate of major and minor bleedings. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
21. Effects of Ile164 Polymorphism of Beta2-Adrenergic Receptor Gene on Coronary Artery Disease
- Author
-
Piscione, Federico, Iaccarino, Guido, Galasso, Gennaro, Cipolletta, Ersilia, Rao, Maria Assunta, Brevetti, Gregorio, Piccolo, Raffaele, Trimarco, Bruno, and Chiariello, Massimo
- Subjects
- *
GENETIC polymorphisms , *POPULATION genetics , *CHROMOSOME polymorphism , *FIBRINOGEN polymorphisms - Abstract
Objectives: This study investigated the relationship between beta2-adrenergic receptor (B2AR) Ile164 polymorphism and coronary artery disease (CAD). Background: B2ARs are crucial to the regulation of vascular tone, and neoangiogenesis is impaired in the presence of isoleucine at position 164 (Ile164) B2AR gene polymorphism. No data deal with the role of the variants at position 164 of the B2AR gene in the setting of CAD. Methods: The study population consisted of 330 patients undergoing percutaneous coronary intervention (PCI). Results: The Ile164 polymorphism frequency was higher in CAD (12.1% vs. 3%, p = 0.008) with respect to the control population. We divided our population into 2 groups: group 1 (290 patients, threonine/threonine genotype at position 164 [164Thr/Thr]) and group 2 (40 patients, threonine/isoleucine genotype at position 164 [164Thr/Ile]). Patients of group 2 presented an earlier onset of CAD (56.7 ± 7.8 vs. 59.5 ± 10, p = 0.04) and a higher incidence of multivessel disease (25.4% vs. 41%, p = 0.044). At follow-up, group 2 showed a higher incidence of new acute myocardial infarction (17.5% vs. 4.5%, p = 0.001), new PCI (37.5% vs. 13.1%, p < 0.0001), and cardiac death (10% vs. 3.1%, p = 0.036). Cox regression analysis identified Ile164 as an independent predictor of cardiac death (odds ratio [OR]: 3.731, 95% confidence interval [CI]: 1.004 to 13.867, p = 0.049) and an overall major adverse cardiac event (OR: 4.100, 95% CI: 1.945 to 8.640, p = 0.0001). A replication study was done on a population of 150 patients with peripheral artery disease. The presence of the Ile164 allele was associated with a higher incidence of acute myocardial infarction (54.5% vs. 25.2%, p = 0.035) or combined events (acute myocardial infarction, PCI, or coronary artery bypass graft) (63.6% vs. 30.9%, p = 0.027). Conclusions: Our study suggests that the B2AR Ile164 mutant is associated with a more aggressive CAD and adversely affects prognosis in patients undergoing PCI. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
22. An active lifestyle improves outcome of primary angioplasty in elderly patients with acute myocardial infarction.
- Author
-
Rengo, Giuseppe, Galasso, Gennaro, Piscione, Federico, Golino, Luca, Fortunato, Francesca, Zincarelli, Carmela, Cassese, Salvatore, Abete, Pasquale, Chiariello, Massimo, Rengo, Franco, and Leosco, Dario
- Subjects
MYOCARDIAL infarction ,CORONARY disease ,CARDIOVASCULAR diseases ,MULTIVARIATE analysis - Abstract
Background: Regular physical activity has been shown to improve outcome of acute myocardial infarction (AMI) in the elderly population. The aim of this study was to evaluate whether the positive role of an active lifestyle on cardiac prognosis extends to elderly patients with AMI who undergo primary percutaneous transluminal coronary angioplasty (PTCA). Methods: We prospectively studied 180 patients with AMI aged ≥70 years and treated with primary PTCA. In all patients, physical activity levels before AMI were quantified by a score derived from the Physical Activity Scale for the Elderly (PASE). Cardiac deaths and nonfatal cardiac events were evaluated within 30 days and 1-year from primary PTCA. Results: A high PASE score was significantly associated with a strong reduction of 30-day cardiac deaths (from 23.1% to 4%; P for trend = .021) and overall nonfatal events (from 21.1% to 10%; P for trend = .01). Accordingly, at 1 year of follow-up, the incidence of cardiac mortality and nonfatal events significantly decreased with increasing PASE score (from 28.8% to 8% and from 55.7% to 14.5%, respectively). Logistic regression analysis indicated that physical activity before AMI was an independent predictor of increased survival in those patients that showed the highest PASE scores. In addition, at 6 months of follow-up, although low ejection fraction and recurrent angina strongly predicted 1-year mortality, high PASE scores still predicted a better outcome. Conclusions: Our data indicate that an active lifestyle may favorably affect early and late outcomes of primary PTCA in the elderly population. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
23. Thoracic aortic emergencies: impact of endovascular surgery.
- Author
-
Iannelli, Gabriele, Piscione, Federico, Di Tommaso, Luigi, Monaco, Mario, Chiariello, Massimo, and Spampinato, Nicola
- Subjects
AORTIC valve diseases ,TOMOGRAPHY ,ANGIOGRAPHY ,PATIENTS - Abstract
: BackgroundConventional surgery for thoracic aortic emergencies, such as contained or free rupture of thoracic aortic aneurysms, acute type B dissections, and traumatic rupture of the thoracic aorta, is frequently associated with a high rate of mortality and morbidity. To obviate this risk, endovascular surgery is considered to be a valid alternative procedure.: MethodsFrom March 2001 to July 2002, 15 of 22 patients with acute thoracic aortic syndromes were submitted to endovascular surgery: 3 patients (20%) for traumatic rupture, 4 patients (26.7%) for contained or free rupture of thoracic aortic aneurysm, and 8 patients (53.3%) for acute type B dissection evolving to rupture. Computed tomographic scan was diagnostic in all patients. The stent grafts were introduced through the femoral artery.: ResultsIn the endovascular group there were no perioperative deaths or open conversions. The intraoperative angiography and computed tomographic scan performed on discharge showed no significant endoleaks and successful sealing of the aortic dissection. Average intensive care unit and hospital stay was 1.7 ± 0.8 and 5.9 ± 3.0 days. Follow-up ranged between 4 and 23 months and included clinical examinations and serial computed tomographic scan at 3, 6, and 12 months, and every 6 months thereafter. One 84-year-old patient with thoracic aortic aneurysm died of pneumonia 78 days after endovascular surgery. Only one type 1 endoleak was noted in the first patient with traumatic rupture, 3 months after the procedure.: ConclusionsEndovascular surgery is a safe technique, showing encouraging early and midterm results and allowing for prompt treatment of associated lesions in complex multitrauma patients. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
24. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic...
- Author
-
Betochhi, Sandro and Piscione, Federico
- Subjects
- *
HYPERTROPHIC cardiomyopathy , *HEMODYNAMICS - Abstract
Aims at assessing the effects of diltiazem on hemodynamics and on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy in an invasive study by cardiac catheterization and simultaneous radionuclide angiography. Marked increase in obstruction in pulmonary artery wedge pressure; Left ventricular pressure-volume analysis.
- Published
- 1996
- Full Text
- View/download PDF
25. Independent Impact of RV Involvement on In-Hospital Outcome of Patients With Takotsubo Syndrome.
- Author
-
Citro, Rodolfo, Bossone, Eduardo, Parodi, Guido, Rigo, Fausto, Nardi, Federico, Provenza, Gennaro, Zito, Concetta, Novo, Giuseppina, Vitale, Giovanni, Prota, Costantina, Silverio, Angelo, Vriz, Olga, D’Andrea, Antonello, Antonini-Canterin, Francesco, Salerno-Uriarte, Jorge, and Piscione, Federico
- Published
- 2016
- Full Text
- View/download PDF
26. Stress-induced cardiomyopathy in pheochromocytoma: the way we treat and the way we think.
- Author
-
Di Maio, Marco, Polito, Maria Vincenza, Citro, Rodolfo, and Piscione, Federico
- Published
- 2014
- Full Text
- View/download PDF
27. Reply: Complexity of Assessment and Management of Tako-Tsubo Cardiomyopathy.
- Author
-
Citro, Rodolfo, Salerno-Uriarte, Jorge, Rigo, Fausto, Parodi, Guido, Ciampi, Quirino, Antonini-Canterin, Francesco, Bossone, Eduardo, and Piscione, Federico
- Published
- 2014
- Full Text
- View/download PDF
28. Reply: What Truly Causes the Adverse Outcome in Tako-Tsubo Cardiomyopathy?
- Author
-
Citro, Rodolfo, Salerno-Uriarte, Jorge, Rigo, Fausto, Parodi, Guido, Ciampi, Quirino, Antonini-Canterin, Francesco, Bossone, Eduardo, and Piscione, Federico
- Published
- 2014
- Full Text
- View/download PDF
29. A peculiar etiology of acute heart failure: adrenergic myocarditis.
- Author
-
Polito, Maria Vincenza, Ravera, Amelia, Silverio, Angelo, Prota, Costantina, Lambiase, Catello, Dellegrottaglie, Santo, Ascoli, Roberto, Farina, Rosario, Citro, Rodolfo, and Piscione, Federico
- Abstract
Pheochromocytoma can occur with a variety of cardiovascular signs and symptoms, and this tumor can also precipitate an acute heart failure associated with the typical clinical and instrumental findings of myocarditis. This peculiar etiology of acute myocarditis, known as “adrenergic myocarditis,” should be suspected when specific “red flags” of pheochromocytoma such as headache, palpitations, diaphoresis, hypertension, orthostatic hypotension, and left ventricular dysfunction suggesting Takotsubo syndrome are detected. In fact, its diagnosis allows a specific targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
30. CRT-103 NSTEMI In Elderly Patients Treated With Early Revascularization: Long-term Outcome.
- Author
-
D' Anna, Carolina, Piscione, Federico, De Luca, Giuseppe, Rapacciuolo, Antonio, Esposito, Giovanni, Cirillo, Plinio, Luciano, Rossella, De Biase, Chiara, Trimarco, Bruno, and Galasso, Gennaro
- Published
- 2015
- Full Text
- View/download PDF
31. Routine invasive management early after fibrinolysis: Relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials.
- Author
-
Bagai, Akshay, Tan, Mary, Di Mario, Carlo, Halvorsen, Sigrun, Cantor, Warren J., Le May, Michel R., Fernandez-Aviles, Francisco, Scheller, Bruno, Armstrong, Paul W., Borgia, Francesco, Piscione, Federico, Sánchez, Pedro L., Westerhout, Cynthia M., Goodman, Shaun G., and Yan, Andrew T.
- Abstract
Background The efficacy of a routine invasive strategy early after fibrinolysis in relation to baseline risk status is unclear. We sought to characterize the interaction between patient risk and treatment with routine invasive strategy early after fibrinolysis for ST-segment elevation myocardial infarction. Methods We pooled 2,974 patients from 7 randomized trials of fibrinolysis-treated patients with ST-segment elevation myocardial infarction comparing a routine early invasive strategy with a standard approach of percutaneous coronary intervention (PCI) guided by recurrent ischemia or need for rescue. Cox proportional hazards regression was used to examine the interaction between baseline patient risk classified by Thrombolysis in Myocardial Infarction risk score (low/intermediate: ≤5 [n = 2,697] vs high: >5 [n = 277]) and treatment with routine early invasive strategy. Results Time to PCI after fibrinolysis was longer among patients randomized to standard treatment compared with routine early invasive strategy in the low/intermediate-risk strata (median 11.4 vs 3.5 hours), but was only marginally different between the 2 groups in the high-risk strata (median 4.1 vs 3.5 hours). There was a significant interaction between treatment assignment and risk status for the composite of 30-day death or reinfarction ( P = .01). Compared with standard treatment, routine early invasive strategy was associated with lower 30-day death/reinfarction in the low/intermediate-risk stratum (7.5% vs 4.0%, P < .001), but not in the high-risk stratum (14.9% vs 19.6%, P = .45). Conclusions Although clearly beneficial among the larger subgroup of patients at low/intermediate risk, the benefit of a routine early invasive strategy was not evident in the smaller subgroup of higher-risk patients in the context of an increased requirement for urgent PCI in the comparative standard treatment arm. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
32. Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: The INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
- Author
-
Biondi-Zoccai, Giuseppe, Valgimigli, Marco, Margheri, Massimo, Marzocchi, Antonio, Lettieri, Corrado, Stabile, Amerigo, Petronio, A. Sonia, Binetti, Giorgio, Bolognese, Leonardo, Bellone, Pietro, Sardella, Gennaro, Contarini, Marco, Sheiban, Imad, Marra, Sebastiano, Piscione, Federico, Romeo, Francesco, Colombo, Antonio, and Sangiorgi, Giuseppe
- Abstract
Background: The optimal antiplatelet regimen in elective patients undergoing complex percutaneous coronary interventions (PCIs) is uncertain. We aimed to assess the impact of glycoprotein IIb/IIIa (GpIIb/IIIa) inhibition with eptifibatide in clinically stable subjects with diffuse coronary lesions. Methods: Patients with stable coronary artery disease undergoing PCI by means of implantation of >33 mm of drug-eluting stent were single-blindedly randomized to heparin plus eptifibatide versus heparin alone. The primary end point was the rate of abnormal post-PCI creatine kinase–MB mass values. Secondary end points were major adverse cardiovascular events (MACEs) (ie, cardiac death, myocardial infarction, or urgent revascularization) and MACE plus bailout GpIIb/IIIa inhibitor use. Results: The study was stopped for slow enrollment and funding issues after including a total of 91 patients: 44 were randomized to heparin plus eptifibatide, and 47, to heparin alone. Analysis for the primary end point showed a trend toward lower rates of abnormal post-PCI creatine kinase–MB mass values in the heparin-plus-eptifibatide group (18 [41%]) versus the heparin-alone group (26 [55%], relative risk 0.74 [95% CI 0.48-1.15], P = .169). Similar nonstatistically significant trends were found for rates of MACE, their components, or MACE plus bailout GpIIb/IIIa inhibitors (all P > .05). Notably, heparin plus eptifibatide proved remarkably safe because major bleedings or minor bleeding was uncommon and nonsignificantly different in both groups (all P > .05). Conclusions: Given its lack of statistical power, the INSTANT study cannot definitively provide evidence against or in favor of routine eptifibatide administration in stable patients undergoing implantation of multiple drug-eluting stent for diffuse coronary disease. However, the favorable trend evident for the primary end point warrants further larger randomized studies. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
33. EARLY PCI AFTER THROMBOLYSIS VERSUS STANDARD THERAPY IN STEMI PATIENTS: A CUMULATIVE META-ANALYSIS
- Author
-
Piscione, Federico, Cantor, Warren J., Fernandez-Aviles, Francisco, Halvorsen, Sigrun, Le-May, Michel, Armstrong, Paul W., Bruno, Scheller, Goodman, Shaun G., Dimopoulos, Konstantinos, Borgia, Francesco, and Di Mario, Carlo
- Published
- 2010
- Full Text
- View/download PDF
34. AS-235: A New Approach to Percutaneous Coronary Revascularization in Patients Requiring Undeferrable Non Cardiac Surgery
- Author
-
Piscione, Federico, Galasso, Gennaro, Cassese, Salvatore, Esposito, Giovanni, Cirillo, Plinio, Rapacciuolo, Antonio, DeRosa, Roberta, Piccolo, Raffaele, and Chiariello, Massimo
- Published
- 2009
- Full Text
- View/download PDF
35. AS-39: Multicenter Experience with Janus Flex Carbostent in Patients Treated with Short Dual-Antiplatelet Treatment, 2 or 6 Months: The MATRIX Study
- Author
-
Piscione, Federico, Marraccini, Paolo, DeLuca, Giuseppe, Bellone, Pietro, Berti, Sergio, Villari, Bruno, Montinaro, Antonio, Alfieri, Alfonso, Quaranta, Gaetano, Carosio, Giuseppe, DiPede, Francesco, and Tiecco, Fabio
- Published
- 2009
- Full Text
- View/download PDF
36. One-year clinical outcome after successful percutaneous coronary interventions on chronic total occlusions: results from a multicenter prospective study
- Author
-
Olivari, Zoran, Piscione, Federico, Rubartelli, Paolo, Dúrbano, Massimo, Paloscia, Leonardo, Marozzini, Cinzia, Tolaro, Silvio, De Luca, Giuseppe, and Giudice, Paolo
- Published
- 2002
- Full Text
- View/download PDF
37. Meta-Analysis of Randomized Trials Comparing the Effectiveness of Different Strategies for the Treatment of Drug-Eluting Stent Restenosis.
- Author
-
Piccolo, Raffaele, Galasso, Gennaro, Piscione, Federico, Esposito, Giovanni, Trimarco, Bruno, Dangas, George D., and Mehran, Roxana
- Subjects
- *
RANDOMIZED controlled trials , *DRUG-eluting stents , *META-analysis , *CORONARY restenosis , *CORONARY angiography , *PACLITAXEL , *RAPAMYCIN , *THERAPEUTICS - Abstract
The investigators performed a network meta-analysis of randomized trials comparing the effectiveness of currently available strategies for the treatment of drug-eluting stent (DES) restenosis. Despite the widespread use of DES in patients who undergo percutaneous coronary intervention, the optimal treatment for DES restenosis remains poorly defined. A systematic search of electronic resources was performed. The primary end point was diameter stenosis at follow-up angiography. Seven trials were included, enrolling a total of 1,586 patients with 1,728 restenotic lesions. The following treatment options were found: balloon angioplasty (BA) in 343 patients (19.3%), iopromide-based paclitaxel-eluting balloons (PEB) in 343 (21.6%), sirolimus-eluting stents in 441 (27.8%), paclitaxel-eluting stents in 462 (29.1%), and everolimus-eluting stents in 34 (2.2%). Compared with BA, PEB (-17.74%, 95% credible interval [CI] -25.17% to -11.31%), everolimus-eluting stents (-14.93%, 95% CI -33.47% to 1.16%), paclitaxel-eluting stents (-15.3%, 95% CI -22.96% to -8.35%), and sirolimus-eluting stents (-11.08%, 95% CI -17.89% to - 3.4%) had similar reductions in diameter stenosis at follow-up angiography. PEB (85%) and everolimus-eluting stents (68%) had the greatest probabilities for being the best treatment option. Furthermore, PEB were the best treatment in terms of late luminal loss (85%) and binary restenosis (85%). BA had the lowest efficacy with respect to all study end points. In conclusion, in patients with DES restenosis, repeat DES implantation and iopromide-based PEB are valid alternatives. However, PEB had greater angiographic efficacy and therefore should be considered the new benchmark comparator in the treatment of DES restenosis. The use of BA should be discouraged in patients with DES restenosis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
38. Timing of events in STEMI patients treated with immediate PCI or standard medical therapy: Implications on optimisation of timing of treatment from the CARESS-in-AMI trial
- Author
-
Dimopoulos, Konstantinos, Dudek, Dariusz, Piscione, Federico, Mielecki, Waldemar, Savonitto, Stefano, Borgia, Francesco, Murena, Ernesto, Manari, Antonio, Gaspardone, Achille, Ochala, Andrzej, Zmudka, Krzysztof, Bolognese, Leonardo, Steg, Philippe Gabriel, Flather, Marcus, and Di Mario, Carlo
- Subjects
- *
ANGIOPLASTY , *THROMBOLYTIC therapy , *MYOCARDIAL infarction , *HOSPITAL care , *MORTALITY , *REPERFUSION injury - Abstract
Abstract: Objectives: Early angioplasty after thrombolysis is now recommended for ST-elevation myocardial infarction, but the current guidelines propose a wide time-window ranging between 3 and 24h after lytic administration. To identify the optimal timing for PCI after thrombolysis, we analyzed frequency and time course of the adverse events in patients randomized in the multicenter CARESS-in-AMI trial. Methods: 598 high-risk patients with STEMI recruited in the CARESS-in-AMI study, were divided into the Immediate PCI group (IMM, n =298), Rescue PCI group (RES, n =107) and Standard Treatment Arm without rescue PCI (STA, n =193). Results: RES patients had worse pre-procedural TIMI flow and post-procedural blush grade. At 30days, there were 23 deaths: 11 (10.3%) in RES, 9 (3%) in IMM and 3 (1.6%) in STA (p <0.001). There were 22 episodes of refractory ischemia or re-infarction: 17 (8.8%) in the STA group, 4 (1.6%) in IMM and 1 (0.9%) in RES (p <0.001). In the RES group 10/11 (90.9%) deaths occurred before day 5. In the STA group, all deaths and the majority of ischemic events occurred after day 3. A reduction of risk of death was observed if PCI after thrombolysis was performed within 3.35h from initial hospitalization. Conclusions: The mortality benefit of immediate referral to PCI after pharmacological treatment for STEMI derives from a reduction in the time to reperfusion of patients with failed thrombolysis in need of rescue PCI. In patients with evidence of successful reperfusion, “elective” PCI within 3days may be sufficient to reduce the recurrent ischemic events. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
39. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE)
- Author
-
Olivari, Zoran, Rubartelli, Paolo, Piscione, Federico, Ettori, Federica, Fontanelli, Alessandro, Salemme, Luigi, Giachero, Corinna, Di Mario, Carlo, Gabrielli, Gabriele, Spedicato, Leonardo, and Bedogni, Francesco
- Subjects
- *
CORONARY disease , *CARDIOPULMONARY bypass - Abstract
: ObjectivesWe sought to investigate the success rate and the acute and 12-month clinical outcome of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) in the contemporary era.: BackgroundThe technique of PCI involving CTO has improved over time. However, limited data on acute and follow-up results in patients treated with PCI on CTO in recent years are available.: MethodsFour hundred nineteen consecutive patients scheduled for PCI of CTO of ≥30 days of duration were enrolled in 29 centers; 390 CTOs were confirmed in 376 patients in an independent core laboratory. The end points were technical and procedural success, in-hospital and 12-month major adverse cardiac events (MACE) occurrence, and 12-month symptomatic status.: ResultsTechnical and procedural success was obtained in 77.2% and 73.3% of lesions, respectively. In-hospital major adverse cardiac events occurred in 5.1% of patients. Multivariate analysis identified CTO length >15 mm or not measurable, moderate to severe calcifications, duration ≥180 days, and multivessel disease as significant predictors of PCI failure. At 12 months, patients with a successful procedure experienced a lower incidence of cardiac deaths or myocardial infarction (1.05% vs. 7.23%, p = 0.005), a reduced need for coronary artery bypass surgery (2.45% vs. 15.7%, p < 0.0001), and were more frequently free of angina (88.7% vs. 75.0%, p = 0.008) compared with patients who had an unsuccessful procedure.: ConclusionsSuccessful PCI was achieved in a high percentage of CTOs with a low incidence of complications. At one-year follow-up, patients with successful PCI of a CTO had a significantly better clinical outcome than those whose PCI was unsuccessful. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
40. Predictors of outcome in heart failure patients with severe functional mitral regurgitation undergoing MitraClip treatment.
- Author
-
Baldi, Cesare, Citro, Rodolfo, Silverio, Angelo, Di Maio, Marco, De Rosa, Roberta, Bonadies, Domenico, Verolino, Giuseppe, Esposito, Luca, Mastrogiovanni, Generoso, Di Muro, Michele Roberto, Piscione, Federico, and Galasso, Gennaro
- Subjects
- *
MITRAL valve insufficiency , *HEART failure patients , *ATRIAL fibrillation , *HEART failure - Abstract
Abstract Background The prognostic predictors of outcome in patients with functional mitral regurgitation (FMR) undergoing MitraClip implantation (MCi) are still poorly known. The aim of our study is to identify the baseline predictors of outcome in FMR patients candidate to MCi. Methods All patients with symptomatic moderate-to-severe or severe FMR undergoing MCi at our institution were consecutively and prospectively enrolled. Baseline clinical and instrumental data were collected. Primary endpoint was the occurrence of cardiac death; secondary endpoints were all-cause death and the composite of cardiac death or rehospitalization for heart failure. Results 74 patients (mean 71.6 ± 8.3 years) were enrolled. During follow-up (median 416.0 days), the primary endpoint occurred in 15 (20.3%), all-cause death in 26 (35.1%) and the composite endpoint in 25 (33.8%). At multivariate analysis, the left atrial volume index (LAVi; HR:1.02; P = 0.048) and the low peak oxygen uptake (peak VO 2 ; HR:0.73; P = 0.018) increased the risk of cardiac death at follow-up; atrial fibrillation (AF; HR:2.69; P = 0.027) was independently associated to all-cause death and the low level of peak VO 2 was an independent predictor of overall mortality (HR:0.70; P < 0.001) as well as of the composite endpoint (HR:0.73; P < 0.001). The ROC analysis identified a peak VO 2 cut-off of 10.0 mL/kg/min as the best predictor for the three study endpoints; the best LAVi cut-off for cardiac death was 67 mL/m2. Kaplan-Meier analysis for the individual and combined outcome predictors confirmed their significant stratification ability during follow-up. Conclusions Peak VO 2 , along with LAVi and AF, identify FMR patients with the worst prognosis after MCi. Highlights • The MCi eligibility of FMR patients needs a multiparametric evaluation to avoid futility. • Baseline peak VO 2 , LAVi and AF are independent predictors of events after MCi. • In FMR patients peak VO 2 < 10 mL/kg/min carried the worst prognosis after MCi. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
41. Transcoronary Th-17 lymphocytes and acute coronary syndromes: new evidence from the crime scene?
- Author
-
Cirillo, Plinio, Golino, Paolo, Piscione, Federico, Cimmino, Giovanni, Petrillo, Gianluca, Abbate, Gianfranco, and De Palma, Raffele
- Published
- 2011
- Full Text
- View/download PDF
42. Clinical profile and in-hospital outcome of Caucasian patients with takotsubo syndrome and right ventricular involvement.
- Author
-
Citro, Rodolfo, Bossone, Eduardo, Parodi, Guido, Carerj, Scipione, Ciampi, Quirino, Provenza, Gennaro, Zito, Concetta, Prota, Costantina, Silverio, Angelo, Vriz, Olga, D'Andrea, Antonello, Galasso, Gennaro, Baldi, Cesare, Rigo, Fausto, Piepoli, Massimo, Salerno-Uriarte, Jorge, and Piscione, Federico
- Subjects
- *
TAKOTSUBO cardiomyopathy , *RIGHT heart ventricle diseases , *CAUCASIAN race , *DISEASE prevalence , *ADVERSE health care events , *COMORBIDITY , *DISEASES - Abstract
Aim To determine the prevalence, clinical characteristics, in-hospital course and determinants of major adverse events in a cohort of Caucasian patients with Takotsubo syndrome (TTS) and right ventricular involvement (RVi), regardless of left ventricular variant forms. Methods and results The study population consisted of 424 patients (mean age 69.1 ± 11.5 years; female 92.2%) with a diagnosis of TTS divided into two groups according to the presence or absence of RVi. RVi patients (n = 57; 13.4%) showed a higher prevalence of comorbidities, especially respiratory diseases (p = 0.011), and a higher Charlson comorbidity index (CCI; p = 0.006) than non-RVi patients. In-hospital major adverse events (acute heart failure, cardiogenic shock and death) occurred more frequently in RVi patients (p < 0.001). Heart rate and CCI, along with the echocardiographic parameters of wall motion score index, E/e’ ratio, tricuspid annular plane systolic excursion (TAPSE) and systolic pulmonary artery pressure (sPAP) were associated with adverse in-hospital outcome. At multivariate analysis, CCI (HR: 1.871; 95% CI: 1.202–2.912; p = 0.006), sPAP (HR: 1.059; 95% CI: 1.016–1.104; p = 0.007) and TAPSE (HR: 0.728; 95% CI: 0.619–0.855; p < 0.001) were independent correlates of the composite outcome in patients with RVi. Conclusion Patients with RVi are characterized by distinct clinical profile and should undergo closely clinical and echocardiographic monitoring. The presence of echocardiographic signs of right ventricular failure along with substantial comorbidities burden identify a cohort at higher risk of in-hospital major adverse cardiovascular events. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
43. 1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention.
- Author
-
Piccolo, Raffaele, Eitel, Ingo, Galasso, Gennaro, Dominguez-Rodriguez, Alberto, Iversen, Allan Zeeberg, Abreu-Gonzalez, Pedro, Windecker, Stephan, Thiele, Holger, and Piscione, Federico
- Subjects
- *
MYOCARDIAL infarction , *ABCIXIMAB (Drug) , *PEOPLE with diabetes , *PERCUTANEOUS coronary intervention , *INTRAVENOUS injections , *MEDICAL care research , *PATIENTS , *CARDIOVASCULAR system , *COMPARATIVE studies , *CORONARY arteries , *DIABETES , *IMMUNOGLOBULINS , *INTRA-arterial injections , *LONGITUDINAL method , *MAGNETIC resonance imaging , *RESEARCH methodology , *MEDICAL care , *MEDICAL cooperation , *MONOCLONAL antibodies , *MYOCARDIUM , *RESEARCH , *TIME , *EVALUATION research , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *PLATELET aggregation inhibitors - Abstract
Background: Diabetic patients are at increased risk for future cardiovascular events after ST-segment elevation myocardial infarction (STEMI). Administration of an intracoronary abciximab bolus during primary percutaneous coronary intervention (PCI) may be beneficial in this high-risk subgroup.Objectives: This study sought to report the 1-year clinical outcomes and cardiac magnetic resonance (CMR) findings in STEMI patients with and without diabetes randomized to intracoronary or intravenous abciximab bolus at the time of primary PCI.Methods: Patient-level data from 3 randomized trials were pooled. The primary endpoint was the composite of death or reinfarction. Comprehensive CMR imaging was performed in 1 study.Results: Of 2,470 patients, 473 (19%) had diabetes and 1,997 (81%) did not. At 1 year, the primary endpoint was significantly reduced in diabetic patients randomized to intracoronary abciximab compared with those randomized to intravenous bolus (9.2% vs. 17.6%; hazard ratio [HR]: 0.49; 95% confidence interval [CI]: 0.28 to 0.83; p = 0.009). The intracoronary abciximab bolus did not reduce the primary endpoint in patients without diabetes (7.4% vs. 7.5%; HR: 0.95; 95% CI: 0.68 to 1.33; p = 0.77), resulting in a significant interaction (p = 0.034). Among diabetic patients, intracoronary versus intravenous abciximab bolus was associated with a significantly reduced risk of death (5.8% vs. 11.2%; HR: 0.51; 95% CI: 0.26 to 0.98; p = 0.043) and definite/probable stent thrombosis (1.3% vs. 4.8%; HR: 0.27; 95% CI: 0.08 to 0.98; p = 0.046). At CMR (n = 792), the myocardial salvage index was significantly increased only in diabetic patients randomized to intracoronary compared with intravenous abciximab (54.4; interquartile range: 35.1 to 78.2 vs. 39.0, interquartile range: 24.7 to 61.7; p = 0.011; p for interaction vs. no diabetes = 0.016).Conclusions: In diabetic patients with STEMI, the administration of intracoronary abciximab improved the effectiveness of primary PCI compared with the intravenous bolus. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
44. Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trials.
- Author
-
Graham, John J., Yan, Andrew T., Tan, Mary K., Cantor, Warren J., DiMario, Carlo, Jolly, Sanjit S., Halvorsen, Sigrun, Fernandez-Aviles, Francisco, Le May, Michel R., Scheller, Bruno, Borgia, Francesco, Piscione, Federico, Madan, Mina, and Goodman, Shaun G.
- Subjects
- *
MYOCARDIAL infarction treatment , *PERCUTANEOUS coronary intervention , *FIBRINOLYSIS , *CLINICAL trials , *HEMORRHAGE , *MORTALITY , *CARDIOVASCULAR system , *CHI-squared test , *COMPARATIVE studies , *FEMORAL artery , *INTRAVENOUS catheterization , *RESEARCH methodology , *MEDICAL care , *MEDICAL cooperation , *MULTIVARIATE analysis , *PROBABILITY theory , *RESEARCH , *RISK assessment , *OPERATIVE surgery , *THROMBOLYTIC therapy , *TIME , *DISEASE relapse , *LOGISTIC regression analysis , *EVALUATION research , *TREATMENT effectiveness , *RADIAL artery , *HOSPITAL mortality , *ODDS ratio - Abstract
Background: To investigate the relationship between arterial access site choice (radial versus femoral) and clinical outcomes among STEMI patients undergoing routine PCI after fibrinolysis.Methods: Patient-level data from trials of STEMI patients evaluating routine PCI after fibrinolysis were included. The primary endpoint was 30-day major bleeding; secondary endpoints included 30-day death and re-infarction.Results: 1891 patients underwent PCI (trans-radial n=338, trans-femoral n=1553). Trans-radial PCI patients were less likely to be >75years (2% vs. 8%, p=0.0001), heavier (median weight 82 [72-90] vs. 80 [70-90] kg, p=0.0013) and more likely in Killip class I at presentation (87% vs. 82%, p=0.03). At 30days, trans-radial PCI was associated with a similar unadjusted risk for major bleeding (3.7% vs. 1.2%, Odds Ratio [OR] 0.43 [95% CI 0.13-1.48], p=0.18), mortality (3.4% vs. 1.2%, OR 0.34 [0.09-1.28], p=0.11) and re-infarction (3.9% vs. 4.7%, OR 1.25 [0.60-2.58], p=0.56). In multivariable analysis, radial access was associated with similar estimates for bleeding and death/reinfarction risk.Conclusions: In STEMI patients treated with fibrinolysis and undergoing an early routine invasive strategy, radial compared to femoral PCI is chosen in younger, less ill patients and is independently associated with similar risk of bleeding, re-infarction, and mortality.Summary: This study evaluated the relationship between arterial access choice (radial versus femoral) and in-hospital and 30-day outcomes in patients undergoing routine PCI after fibrinolysis for STEMI. We included patient-level data from trials evaluating a strategy of routine PCI after fibrinolysis for STEMI. Of 1891 patients undergoing PCI, trans-radial access (n=338) was chosen in younger, lower risk patients. At 30days, trans-radial access was associated with a similar unadjusted and adjusted risk of major bleeding, re-infarction and mortality. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
45. Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
- Author
-
Piccolo, Raffaele, Eitel, Ingo, Galasso, Gennaro, Iversen, Allan Zeeberg, Gu, Youlan L., Dominguez-Rodriguez, Alberto, de Smet, Bart J.G.L., Mahmoud, Karim D., Abreu-Gonzalez, Pedro, Thiele, Holger, and Piscione, Federico
- Subjects
- *
MYOCARDIAL infarction , *TREATMENT of diabetes , *PEOPLE with diabetes , *ABCIXIMAB (Drug) , *PERCUTANEOUS coronary intervention , *DRUG administration , *PATIENTS - Abstract
Background Although intracoronary abciximab failed to improve prognosis compared with intravenous route in unselected ST-segment elevation myocardial infarction (STEMI) patients, little is known about the role of intracoronary abciximab in diabetic patients. Objectives To evaluate the efficacy of intracoronary abciximab administration in diabetic patients with STEMI undergoing primary percutaneous coronary intervention (PCI). Methods Reperfusional and clinical outcomes of intracoronary abciximab compared with intravenous bolus abciximab according to diabetic status were evaluated in a pooled analysis of five randomized trials including 3158 STEMI patients. The primary clinical endpoint of the study was the composite of death or reinfarction at 30-day follow-up. Results Among 584 diabetic patients (18.5%), the composite of death or reinfarction was significantly reduced with intracoronary abciximab compared to intravenous abciximab (4.7% vs. 8.8%; rate ratio [RR], 0.50; 95% confidence intervals [CI], 0.26–0.99; p = 0.04), driven by numerically lower deaths (3.7% vs. 6.4%; RR, 0.56; 95% CI, 0.26–1.20; p = 0.13). Moreover, a significant reduction in definite or probable stent thrombosis was observed in patients receiving intracoronary abciximab (1% vs. 3.5%; RR, 0.27; 95% CI, 0.07–0.99; p = 0.04). Although formal tests for interaction were not significant, no clinical benefit was apparent in the cohort of STEMI patients without diabetes (n = 2574). Conclusions In diabetic patients with STEMI undergoing primary PCI, intracoronary abciximab may improve clinical outcomes as compared with standard intravenous use. These findings require confirmation in a dedicated randomized trial. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
46. Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure.
- Author
-
Gandhi, Parul U., Gaggin, Hanna K., Belcher, Arianna M., Harisiades, Jamie E., Basile, Anna, Falco, Antonia, Rosati, Alessandra, Piscione, Federico, Jr.Januzzi, James L., and Turco, M. Caterina
- Subjects
- *
BAK protein , *HEART failure , *BLOOD testing , *HEART failure treatment , *BLOOD plasma , *MEDICAL statistics , *PROGNOSIS - Abstract
Background BCL-2-associated athanogene 3 (BAG3) is a protein implicated in the cardiomyocyte stress response and genesis of cardiomyopathy. Extracellular BAG3 is measurable in patients with heart failure (HF), but the relationship of BAG3 with HF prognosis is unclear. Methods BAG3 plasma concentrations were measured in 39 acutely decompensated HF patients; the primary endpoint was death at 1 year. Baseline characteristics were compared by vital status and median BAG3 concentration. Correlation of BAG3 with left ventricular ejection fraction (LVEF) and other biomarkers was performed. Prognostic value was assessed using Cox proportional hazards regression and Kaplan–Meier analysis. Results At baseline, median BAG3 was significantly higher in decedents (N = 11) than survivors (N = 28; 1489 ng/mL versus 50 ng/mL; P = 0.04); decedents also had worse renal function and higher median natriuretic peptide (NP) and sST2. BAG3 was not significantly correlated with NPs, mid-regional pro-adrenomedullin, sST2, or eGFR, however. Mortality was increased in patients with supra-median BAG3 (> 336 ng/mL; 42.1% versus 15.0%, P = 0.06). In age and LVEF-adjusted Cox proportional hazards, BAG3 remained a significant mortality predictor (HR = 3.20; 95% CI = 1.34–7.65; P = 0.02); those with supra-median BAG3 had significantly shorter time-to-death (P = 0.04). Conclusion The stress response protein BAG3 is measurable in patients with ADHF and may be prognostic for death. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
47. Effect of an Invasive Strategy on Outcome in Patients ≥75 Years of Age With Non-ST-Elevation Acute Coronary Syndrome.
- Author
-
Galasso, Gennaro, De Servi, Stefano, Savonitto, Stefano, Strisciuglio, Teresa, Piccolo, Raffaele, Morici, Nuccia, Murena, Ernesto, Cavallini, Claudio, Petronio, Anna Sonia, and Piscione, Federico
- Subjects
- *
RANDOMIZED controlled trials , *ACUTE coronary syndrome , *TREATMENT of acute coronary syndrome , *HOSPITAL care , *CORONARY angiography , *MYOCARDIAL infarction , *CORONARY heart disease prevention , *PATIENTS - Abstract
The Italian Elderly ACS study was the first randomized controlled trial comparing an early aggressive with an initially conservative strategy in patients with non-ST-segment elevation acute coronary syndromes aged = 75 years, with the results showing no significant benefit of early aggressive therapy. The aim of this study was to evaluate the outcomes of trial patients, according to the treatment actually received during hospitalization. The trial enrolled 313 patients. The primary end point was the composite of death, myocardial infarction (MI), disabling stroke, and repeat hospital stay for cardiovascular causes or bleeding within 1 year. All patients in whom coronary angiography was performed during initial hospitalization were defined as having undergone invasive treatment (182 patients), whereas all patients who did not undergo coronary angiography were classified as medically managed (conservative treatment [CT] group, 131 patients). The primary end point occurred in 53 patients (40.5%) in the CT group and 45 patients (24.7%) in the invasive treatment group (hazard ratio 0.56, 95% confidence interval 0.37 to 0.83, p = 0.003). The invasive treatment group showed significantly lower rates of MI (6% vs 13% in the CT group; hazard ratio 0.43, 95% confidence interval 0.20 to 0.92, p = 0.034) and the aggregate of death and MI (14.3% vs 27.5% CT group; hazard ratio 0.48, 95% confidence interval 0.29 to 0.81, p = 0.004). In conclusion, elderly patients with non-ST-segment elevation acute coronary syndromes treated invasively experienced significantly better survival free from the composite of all-cause mortality, nonfatal MI, disabling stroke, and repeat hospitalization for cardiovascular causes or bleeding. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
48. Effects of Baseline Coronary Occlusion and Diabetes Mellitus in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
- Author
-
Piccolo, Raffaele, Galasso, Gennaro, Iversen, Allan Zeeberg, Eitel, Ingo, Alberto Dominguez-Rodriguez, Gu, Youlan L., de Smet, Bart J.G.L., Mahmoud, Karim D., Pedro Abreu-Gonzalez, Trimarco, Bruno, Thiele, Holger, and Piscione, Federico
- Subjects
- *
MYOCARDIAL infarction , *ARTERIAL occlusions , *PEOPLE with diabetes , *ANGIOPLASTY , *ABCIXIMAB (Drug) , *PATIENTS , *DISEASES ,MYOCARDIAL infarction-related mortality - Abstract
Several studies have highlighted the prognostic role of preprocedural Thrombolysis In Myocardial Infarction (TIMI) flow in the infarct-related artery (IRA) in patients with ST-segment elevation myocardial infarction (STEMI). However, the impact of preprocedural IRA occlusion in patients with diabetes with STEMI has been insufficiently studied. The aim of this study was to evaluate the effects of baseline IRA occlusion and diabetic status in patients with STEMI who underwent primary percutaneous coronary intervention by using data from a pooled analysis of randomized trials comparing intracoronary with intravenous abciximab bolus administration. A total of 3,046 patients with STEMI who underwent primary percutaneous coronary intervention were included. Diabetes was present in 578 patients (19%). The primary outcome was mortality after a median follow-up period of 375 days. Secondary end points were reinfarction and stent thrombosis. In patients without diabetes, IRA occlusion versus no occlusion was not associated with increased rates of mortality (4.3% vs 2.7%, p = 0.051) and reinfarction (3.3% vs 2.5%, p = 0.33). Patients with diabetes with IRA occlusion compared with those without occlusion showed higher rates of mortality (10.6% vs 4.6%, p = 0.01) and reinfarction (5.6% vs 2.1%, p = 0.03). Baseline IRA occlusion increased the rate of stent thrombosis in the nondiabetic (2.1% vs 1.0%, p = 0.04) and diabetic (3.2% vs 0.8%, p = 0.05) cohorts. Interaction analysis demonstrated that the risk for death and reinfarction was significantly increased when diabetes and IRA occlusion occurred concomitantly. In conclusion, patients with STEMI with diabetes and baseline IRA occlusion had disproportionately higher rates of death and reinfarction. Preprocedural IRA occlusion increased the risk for stent thrombosis, irrespective of diabetic status. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
49. Reperfusion Correlates and Clinical Outcomes of Right Ventricular Dysfunction in Patients With Inferior ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
- Author
-
Piccolo, Raffaele, Niglio, Tullio, Spinelli, Letizia, Capuano, Ernesto, Strisciuglio, Teresa, D'Anna, Carolina, De Luca, Stefania, Leosco, Dario, Rapacciuolo, Antonio, Cirillo, Plinio, Stabile, Eugenio, Esposito, Giovanni, Trimarco, Bruno, Piscione, Federico, and Galasso, Gennaro
- Subjects
- *
RIGHT heart ventricle , *MYOCARDIAL infarction , *CORONARY angiography , *MYOCARDIAL reperfusion , *HEALTH outcome assessment , *THROMBOLYTIC therapy , *PATIENTS - Abstract
We evaluated the relation between reperfusion indexes and right ventricular (RV) dysfunction in patients with inferior ST-segment elevation myocardial infarction (STEMI). We included patients with inferior STEMI undergoing percutaneous coronary intervention and right coronary artery as infarct-related artery. Myocardial reperfusion was evaluated by Thrombolysis In Myocardial Infarction (TIMI) flow, TIMI frame count, myocardial blush grade, and STsegment resolution. RV dysfunction was defined as tricuspid annular plane systolic excursion ≤16 mm in M-mode imaging. RV dysfunction was present in 58 of 141 patients (41.1%) and was more frequent in patients achieving suboptimal postprocedural TIMI flow grade (66.7% vs 36.7%, grades 0 to 2 vs 3, p = 0.01), TIMI frame count (63.2% vs 37.7%, 40 vs <40 frames, p = 0.04), and myocardial blush grade (33.3% vs 56.2%, grade 0 or 1 vs 2 or 3, p = 0.001). RV dysfunction rates did not differ according to ST-segment resolution. Patients with RV dysfunction had increased rates of cardiac death (13.2% vs 2.6%, p = 0.03), reinfarction (24.5% vs 10.3%, p = 0.03), and stent thrombosis (22.6% vs 6.4%, p = 0.01) at 2-year follow-up. Postprocedural TIMI flow grade 3 (odds ratio 0.25, 95% confidence interval 0.09 to 0.68, p = 0.007) was the only reperfusion correlate of RV dysfunction at multivariate analysis. In an independent cohort of 84 patients with STEMI, postprocedural TIMI flow grade 3 had a limited sensitivity (52%), with a high specificity (74.5%) and negative predictive value (71%) for excluding RV dysfunction. In conclusion, in patients with inferior STEMI undergoing coronary revascularization, RV dysfunction is associated with a worse long-term prognosis. Postprocedural TIMI flow grade may be a useful tool to predict RV dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
50. Relationship between changes in platelet reactivity and ischemic events following percutaneous coronary intervention: A meta-regression analysis of 30 randomized trials.
- Author
-
Piccolo, Raffaele, Galasso, Gennaro, De Luca, Giuseppe, Parodi, Guido, Antoniucci, David, Esposito, Giovanni, Trimarco, Bruno, and Piscione, Federico
- Subjects
- *
ISCHEMIA , *ANGIOPLASTY , *ADVERSE health care events , *CLINICAL trials , *PLATELET aggregation inhibitors , *FOLLOW-up studies (Medicine) - Abstract
Abstract: Objective: High on-treatment platelet reactivity (HPR) is a well-known risk factor for adverse events in patients undergoing percutaneous coronary intervention (PCI). However, whether reducing platelet reactivity can lead to a lower incidence of ischemic events after PCI is still controversial. Therefore, we sought to investigate this issue by a meta-regression analysis of randomized trials. Methods: We collected randomized trials reporting HPR rates in patients receiving different antiplatelet therapies. ΔHPR was defined as the difference between HPR rates achieved in control vs. experimental arms, and the relationship between ΔHPR and clinical outcomes was evaluated. Results: Thirty trials totalling 6683 patients with a mean follow-up of 3-month were included. Reducing platelet reactivity was associated to a decreased risk of major adverse cardiac events (MACE), with a linear relationship between ΔHPR and MACE (change in tau2 = −2.50; p = 0.023). Particularly, achieving a 10% difference in HPR rates resulted in a parallel risk reduction in MACE of about 11% (Exp(b) = 0.98; 95% CI, 0.97–0.99). Changes in HPR predict the risk of ischemic events in patients with acute coronary syndrome (change in tau2 = −2.52; Exp(b) = 0.98; 95% CI, 0.97–0.99; p = 0.03), but not in patients with poor response to clopidogrel (change in tau2 = −1.44; Exp(b) = 0.98; 95% CI, 0.96–1.01; p = 0.19) or stable coronary artery disease (change in tau2 = −0.14; Exp(b) = 0.99; 95% CI, 0.94–1.05; p = 0.89). Conclusion: Reducing HPR occurrence decreases the risk of ischemic events in patients with acute coronary syndrome undergoing PCI, whereas a strategy of reducing platelet reactivity does not improve clinical outcomes in patients with poor response to clopidogrel or stable coronary artery disease. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.